SCHEMBL5330741

SCHEMBL5330741

C=CCC(C#N)C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
TSHR P16473 2/20 0.40
GAA P10253 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
CYP2C9 P11712 1/20 0.35
HTT P42858 3/20 0.34
LMNA P02545 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30487652 0.85 ALDH1A1 (0.38) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL6111321 0.84 ALDH1A1 (0.44) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL5325415 0.83 TSHR (0.37) ALDH1A1TSHRMEN1KMT2ANPSR1
SCHEMBL2075362 0.82 ALDH1A1 (0.38) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL11590162 0.81
SCHEMBL10000154 0.80 ALDH1A1 (0.35) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL9718386 0.79 ALDH1A1 (0.38) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL10902100 0.78 ALDH1A1 (0.42) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL10920266 0.78 ALDH1A1 (0.42) ALDH1A1TSHRGAAMEN1KMT2A
SCHEMBL21646322 0.77 USP2 (0.43) ALDH1A1TSHRSMN1; SMN2CYP2C9LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312335-B2 Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts BRANDEIS UNIVERSITY (US) 2007-12-25 US disclosed
EP-1758899-A1 ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS Brandeis University (US) 2007-03-07 EP disclosed
US-20060014956-A1 Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts BRANDEIS UNIVERSITY 2006-01-19 US disclosed
WO-2005121137-A1 ASYMMETRIC MICHAEL AND ALDOL ADDITION USING BIFUNCTIONAL CINCHONA-ALKALOID-BASED CATALYSTS BRANDEIS UNIVERSITY (US) 2005-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014956-A1 Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts ALDH3A1, NQO1, DERA ALDH1A1 13/4885TSHR 4770/4885GAA 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.